UCLA Health is committed to the safety of patients and employees while maintaining high-quality care at our hospitals in Westwood and Santa Monica and community clinics across the region.
As an academic health system that regularly treats patients with complex illnesses and manages a major research enterprise, UCLA Health and the David Geffen School of Medicine at UCLA are uniquely positioned to address the COVID-19 pandemic. We have the clinical expertise, modern facilities, innovative research and dedicated physicians, nurses and staff to meet this challenge. Leveraging resources and expertise allows us to deliver on our mission of patient care, research, medical education and community service.
UCLA Health has made many adjustments to standard operating procedures at its hospitals and clinics. Those changes, summarized below, include testing for COVID-19, screening patients and visitors for symptoms, shifting dramatically toward telehealth and securing supply chains for personal protective equipment and other supplies, among many other steps.
While maintaining readiness if the number of COVID-positive patients significantly increases, UCLA Health is carefully increasing the number of essential surgeries and procedures – focusing on those postponed earlier in the pandemic and those that have become time-sensitive for the patient's condition.
UCLA Health has in place comprehensive, effective infection prevention practices so that patients can feel safe coming in for care. Patients, staff and visitors are screened for fever and symptoms and are provided a facemask before entering our facilities. In addition, all patients are tested for COVID-19 before being admitted to the hospital and most are tested before undergoing an outpatient procedure. Tests are analyzed based on the highest standards by our in-house labs, so we are confident in the results. We have adequate supplies of facemasks and other personal protective equipment to safely provide care.
Here is a summary of some of the steps taken by UCLA Health and the David Geffen School of Medicine at UCLA:
Better Together UCLA Health has joined five other nonprofit health systems in the region to encourage community members to put health first and access care when needed.
Public service announcement | News release
Data about COVID-19 testing volume and results and patients in our hospitals is updated daily and available here.
Screening and Masking Testing and screening for symptoms reduces opportunities for exposure and decreases the likelihood of transmission.
Personal Protective Equipment (PPE) UCLA Health follows Los Angeles County Department of Public Health and U.S. Centers for Disease Control and Prevention guidelines for use of PPE. While we have adequate supplies to safely provide care, it is important to remain vigilant stewards of masks and other PPE.
UCLA Health is grateful for the generosity of many companies, individuals and organizations who have donated PPE. For information about making a financial or in-kind donation, go here.
UCLA Heath is heartened by so many in the community showing their support for health care workers via UCLA Health's #TeamLA campaign.
Telehealth Converting in-person physician visits to telehealth visits allows UCLA Health to serve patients and the community while minimizing opportunities for exposure and decreasing the likelihood of transmission.
Clinical Trials and Research UCLA Health and the David Geffen School of Medicine at UCLA are on the forefront of COVID- 19. Teams have rapidly and strategically mobilized and research is being prioritized.
We have at 15 least active clinical trials on such subjects as treatments for non-hospitalized patients, pre-exposure and vaccine trials, and studies for healthcare workers and first responders, among others.
Visitation To help maintain a safe environment, UCLA Health has temporarily restricted visitor access to facilities. For details, go here.
Maintaining Preparedness We are prepared for the possibility that the number of Covid-positive patients may increase.
A new UCLA clinical trial, COLHEART-19, is testing a currently available anti-inflammatory drug to treat heart damage associated with COVID-19.